H. Javelot, Anne Marquis, B. Michel, Jean Gr, Idier
{"title":"血管紧张素转换酶抑制剂和沙坦在老年环境:治疗交换的影响","authors":"H. Javelot, Anne Marquis, B. Michel, Jean Gr, Idier","doi":"10.4172/2167-7182.1000419","DOIUrl":null,"url":null,"abstract":"Background: Therapeutic interchange is widely used in geriatric settings, such as angiotensin enzyme converting inhibitors and angiotensin II receptor antagonists and angiotensin receptor blockers (sartans). \nObjective: we evaluate the clinical impact (efficacy and tolerance) of a therapeutic interchange program for noncomplicated hypertension. \nMethod: 13 patients receiving angiotensin enzyme converting inhibitors and 7 patients under sartans were followed-up during 6 months after a therapeutic interchange to a first line drug: Ramipril and valsartan, respectively. \nResults: all the substitutions were well tolerated and no significant difference was observed for diastolic and systolic pressure after therapeutic interchange. \nConclusion: therapeutic interchange on angiotensin enzyme converting inhibitors and sartans in the context of hypertension seem safe based on our clinical data.","PeriodicalId":289564,"journal":{"name":"Journal of gerontology and geriatric research","volume":"26 1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Angiotensin Converting Enzyme Inhibitors and Sartans in a Geriatric Setting: Impact of Therapeutic Interchange\",\"authors\":\"H. Javelot, Anne Marquis, B. Michel, Jean Gr, Idier\",\"doi\":\"10.4172/2167-7182.1000419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Therapeutic interchange is widely used in geriatric settings, such as angiotensin enzyme converting inhibitors and angiotensin II receptor antagonists and angiotensin receptor blockers (sartans). \\nObjective: we evaluate the clinical impact (efficacy and tolerance) of a therapeutic interchange program for noncomplicated hypertension. \\nMethod: 13 patients receiving angiotensin enzyme converting inhibitors and 7 patients under sartans were followed-up during 6 months after a therapeutic interchange to a first line drug: Ramipril and valsartan, respectively. \\nResults: all the substitutions were well tolerated and no significant difference was observed for diastolic and systolic pressure after therapeutic interchange. \\nConclusion: therapeutic interchange on angiotensin enzyme converting inhibitors and sartans in the context of hypertension seem safe based on our clinical data.\",\"PeriodicalId\":289564,\"journal\":{\"name\":\"Journal of gerontology and geriatric research\",\"volume\":\"26 1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of gerontology and geriatric research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2167-7182.1000419\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gerontology and geriatric research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-7182.1000419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Angiotensin Converting Enzyme Inhibitors and Sartans in a Geriatric Setting: Impact of Therapeutic Interchange
Background: Therapeutic interchange is widely used in geriatric settings, such as angiotensin enzyme converting inhibitors and angiotensin II receptor antagonists and angiotensin receptor blockers (sartans).
Objective: we evaluate the clinical impact (efficacy and tolerance) of a therapeutic interchange program for noncomplicated hypertension.
Method: 13 patients receiving angiotensin enzyme converting inhibitors and 7 patients under sartans were followed-up during 6 months after a therapeutic interchange to a first line drug: Ramipril and valsartan, respectively.
Results: all the substitutions were well tolerated and no significant difference was observed for diastolic and systolic pressure after therapeutic interchange.
Conclusion: therapeutic interchange on angiotensin enzyme converting inhibitors and sartans in the context of hypertension seem safe based on our clinical data.